GYRE THERAPEUTICS, INC. Quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD from Q4 2021 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary: Gyre Therapeutics, Inc. quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest history and growth rate from Q4 2021 to Q2 2024.
Gyre Therapeutics, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending June 30, 2024 was $93.3M, a 20.5% increase year-over-year.

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q2 2024	$93.3M	+$15.9M	+20.5%	Jun 30, 2024	10-Q	2024-08-13
Q1 2024	$88.8M	+$11.4M	+14.8%	Mar 31, 2024	10-Q	2024-08-13
Q4 2023	$13.9M	-$58.3M	-80.7%	Dec 31, 2023	10-Q	2024-08-13
Q2 2023	$77.5M			Jun 30, 2023	10-Q	2024-08-13
Q1 2023	$77.3M			Mar 31, 2023	10-Q	2024-08-13
Q4 2022	$72.2M	+$12.8M	+21.4%	Dec 31, 2022	10-Q	2024-08-13
Q4 2021	$59.5M			Dec 31, 2021	10-K	2024-03-27

* An asterisk sign (*) next to the value indicates that the value is likely invalid.